When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Carcinoma de células renais

Last reviewed: 24 Sep 2025
Last updated: 12 Dec 2024

Summary

Definition

History and exam

Key diagnostic factors

  • presença de fatores de risco
  • assintomático (achado incidental)
  • hematúria
  • dor no flanco
  • massa abdominal palpável
Full details

Other diagnostic factors

  • sintomas sistêmicos inespecíficos
  • sinais de disfunção hepática
  • mioneuropatia
  • edema de membros inferiores
  • varicocele escrotal
  • manifestações dermatológicas (síndromes hereditárias)
  • perda da visão (Von Hippel-Lindau)
Full details

Risk factors

  • tabagismo
  • sexo masculino
  • idade acima de 55 anos
  • residência em países desenvolvidos
  • etnia indígena norte-americana não hispânica/nativa do Alasca
  • obesidade
  • hipertensão
  • história familiar positiva de CCR
  • história de síndromes hereditárias
  • história de doença renal cística adquirida
  • exposição a asbesto/cádmio
  • história obstétrica/exposição ao estrogênio
  • radiação pélvica
Full details

Diagnostic investigations

1st investigations to order

  • tomografia computadorizada (TC) de abdome/pelve
  • tomografia computadorizada (TC) do tórax
  • RNM de abdome/pelve
  • ultrassonografia abdominal/pélvica
  • Hemograma completo
  • lactato desidrogenase (LDH)
  • cálcio corrigido
  • testes da função hepática
  • perfil de coagulação
  • creatinina
  • TFG estimada
  • urinálise
Full details

Investigations to consider

  • ressonância nuclear magnética (RNM) cranioencefálica/da coluna
  • cintilografia óssea
  • biópsia
  • patologia cirúrgica
  • avaliação genética
Full details

Emerging tests

  • tomografia por emissão de pósitrons (PET)

Treatment algorithm

ONGOING

massa renal pequena ou carcinoma de células renais (CCR) em estádio 1 ou 2

carcinoma de células renais (CCR) em estádio 3

carcinoma de células renais (CCR) em estádio 4 (doença metastática)

Contributors

Authors

Rodrigo R. Pessoa, MD, PhD

Urology Fellow

Department of Urology

Mayo Clinic

Rochester

MN

Disclosures

RRP declares that he has no competing interests.

Simon Kim, MD, MPH

Associate Professor of Surgery

Associate Program Director

Anschutz Medical Campus

University of Colorado

UCSOM Division of Urology

Denver

CO

Disclosures

SK declares that he has no competing interests.

Acknowledgements

Dr Rodrigo R. Pessoa and Dr Simon Kim would like to gratefully acknowledge Dr Amishi Y. Shah, Dr Sonal Gandhi, and Jennifer J. Knox, previous contributors to this topic.

Disclosures

AYS has an unpaid advisory role for Merck pharmaceuticals. SG and JJK declare that they have no competing interests.

Peer reviewers

Stephen A. Boorjian, MD

Assistant Professor

Fox Chase Cancer Center

Philadelphia

PA

Disclosures

SAB has been reimbursed by Pfizer for serving on its speakers bureau. SAB is co-author of a reference cited in this topic.

Thomas J. Guzzo, MD, MPH

Assistant Professor of Urology and Surgery

The Hospital of the University of Pennsylvania

Philadelphia

PA

Disclosures

TJG declares that he has no competing interests.

Jonathan Waxman, BSc, MBBS, MD, FRCP

Professor of Oncology

Imperial College

London

UK

Disclosures

JW declares that he has no competing interests.

Peer reviewer acknowledgements

BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.

Disclosures

Peer reviewer affiliations and disclosures pertain to the time of the review.

References

Our in-house evidence and editorial teams collaborate with international expert contributors and peer reviewers to ensure that we provide access to the most clinically relevant information possible.

Key articles

American Urological Association. Renal mass and localized renal cancer: evaluation, management, and follow up. 2021 [internet publication].Full text

Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment, and follow-up. Ann Oncol. 2019 May;30(5):706-20.Full text  Abstract

European Association of Urology. Renal cell carcinoma. 2023 [internet publication].Full text

American College of Radiology. ACR appropriateness criteria: post-treatment follow-up and active surveillance of clinically localized renal cell carcinoma. 2021 [internet publication].Full text

Rathmell WK, Rumble RB, Van Veldhuizen PJ, et al. Management of metastatic clear cell renal cell carcinoma: ASCO guideline. J Clin Oncol. 2022 Sep 1;40(25):2957-95.Full text  Abstract

Reference articles

A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.
  • Carcinoma de células renais images
  • Differentials

    • Cisto renal benigno
    • Câncer ureteral
    • Câncer de bexiga
    More Differentials
  • Guidelines

    • Suspected cancer: recognition and referral
    • NCCN clinical practice guidelines in oncology: kidney cancer
    More Guidelines
  • Patient information

    Câncer de rim

    More Patient information
  • padlock-lockedLog in or subscribe to access all of BMJ Best Practice

Use of this content is subject to our disclaimer